NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Quanterix Corporation ("Quanterix Corporation") (NASDAQ:QTRX) concerning possible violations of federal securities laws. After the market closed, on November 12, 2024, Quanterix announced that it had "identified an error regarding the capitalization of labor and overhead costs applied to prior periods, dating back to at least 2021," which had affected the valuation of its inventory.
NEW YORK CITY, NY / ACCESSWIRE / November 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX). Investors who purchased Quanterix securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/QTRX.
NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Quanterix Corporation ("Quanterix Corporation") (NASDAQ:QTRX) concerning possible violations of federal securities laws. After the market closed, on November 12, 2024, Quanterix announced that it had "identified an error regarding the capitalization of labor and overhead costs applied to prior periods, dating back to at least 2021," which had affected the valuation of its inventory.
LOS ANGELES, CA / ACCESSWIRE / November 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Quanterix Corporation ("Quanterix Corporation") (NASDAQ:QTRX) concerning possible violations of federal securities laws. After the market closed, on November 12, 2024, Quanterix announced that it had "identified an error regarding the capitalization of labor and overhead costs applied to prior periods, dating back to at least 2021," which had affected the valuation of its inventory.
Quanterix Corporation (NASDAQ:QTRX ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Vandana Sriram - CFO Masoud Toloue - President and CEO Conference Call Participants Jake Allen - Goldman Sachs Sung Ji Nam - Scotiabank Kyle Mikson - Canaccord Genuity Puneet Souda - Leerink Partners Thomas DeBourcy - Nephron Research Operator Thank you for standing by. My name is Andrea and I will be your conference operator today.
Today, we revisit Quanterix Corporation, which provides ultra-sensitive digital assay platforms for detecting protein biomarkers in healthcare. The company has a pristine balance sheet with some $300 million in net cash on it. Quanterix Corporation is also seeing steady revenue growth. Unfortunately, the firm is making little progress on the profitability front but is pushing further into early Alzheimer's detection.
Quanterix Corporation (QTRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.16 per share a year ago.
Quanterix (QTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.